Table 4: MSC therapeutics products on the market. (Data from 2012; sources from official websites of each company, [118,119]).

 

Product

Company

Source of MSC

Jurisdiction (Country)

Indication

Hearticellgram®-AMI

FCB Pharmicell

BM-MSC, Autologous

MFDS (Korea)

Acute Myocardial Infarction

Prochymal®

Mesoblast

BM-MSC, Allogeneic

Health Canada (Canada), Medsafe (New Zealand)

Acute GvHD

CardioRel®

Reliance Life Science

BM-MNCs &MSC, Autologous

CDSCO (India)

Acute Myocardial Infarction

Trinity Evolution®

Orthofix

Demineralized bone matrix with MSC, Allogeneic

FDA (USA)

Musculoskeletal Defects

Allostem®

Allosource

Demineralized bone matrix with adipose MSC, Allogeneic

FDA (USA)

Orthopedics

Cupistem®

Anterogen

Adipose MSC, Autologous

MFDS (Korea)

Crohn’s Disease

Cartistem®

Medipost

Umbilical cord blood MSC, Allogeneic

MFDS (Korea)

Degenerative Arthritis

ReliNethra

Reliance Life Science

Limbal epithelial stem cells, Autologous

CDSCO (India)

Eye Diseases

Osteocel® Plus

NuVasive

MSC and osteoprogenitor cells, Allogeneic

FDA (USA)

Orthopedics

 

Abbreviations: MFDS: Ministry of Food and Drug Safety; CDSCO: Central drugs standard control organization; FDA: Food and Drug administration